Zhangzhou Pientzehuang Pharmaceutical
1
30M
1
0.05
- Areas of investment
Summary
Zhangzhou Pientzehuang Pharmaceutical is the famous Corporate Investor, which was founded in 1999. The main office of represented Corporate Investor is situated in the Zhangzhou. The fund was located in Asia if to be more exact in China.
The typical case for the fund is to invest in rounds with 3 participants. Despite the Zhangzhou Pientzehuang Pharmaceutical, startups are often financed by Jianxin Capital. The meaningful sponsors for the fund in investment in the same round are SDIC Fund Management, CMB International Capital Corporation.
The usual things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2017. The fund is generally included in less than 2 deals every year.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Among the various public portfolio startups of the fund, we may underline LP Pharmaceuticals Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Biopharma, Pharmaceutical.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Rounds per year
- 0.05
- Investments by industry
- Pharmaceutical (1)
- Delivery (1)
- Biopharma (1)
- Investments by region
-
- China (1)
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 9
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| LP Pharmaceuticals | 20 Dec 2017 | Delivery, Pharmaceutical, Biopharma | Early Stage Venture | 30M | China, Fujian, Siming |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.